I am a
Home I AM A Search Login

Papers of the Week

Papers: 24 Sep 2022 - 30 Sep 2022

Animal Studies, Pharmacology/Drug Development

2022 Sep 23

J Transl Med



Editor's Pick

Soluble CCR2 gene therapy controls joint inflammation, cartilage damage, and the progression of osteoarthritis by targeting MCP-1 in a monosodium iodoacetate (MIA)-induced OA rat model.


Na H S, Lee S-Y, Lee D H, Woo J S, Choi S-Y, Cho K-H, Kim S A, Go E J, Lee RA, Choi J-W, Kim S J, Cho M-L
J Transl Med. 2022 Sep 23; 20(1):428.
PMID: 36138477.


Osteoarthritis (OA) is the most common type of degenerative arthritis and affects the entire joint, causing pain, joint inflammation, and cartilage damage. Various risk factors are implicated in causing OA, and in recent years, a lot of research and interest have been directed toward chronic low-grade inflammation in OA. Monocyte chemoattractant protein-1 (MCP-1; also called CCL2) acts through C-C chemokine receptor type 2 (CCR2) in monocytes and is a chemotactic factor of monocytes that plays an important role in the initiation of inflammation. The targeting of CCL2-CCR2 is being studied as part of various topics including the treatment of OA.